PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Last trade$1.20
Day change+$0.01 (+0.84%)
Day range$1.08 – $1.30
Volume651,182
Market cap$90M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$89.89M
Price / earnings
—
Price / book
1.57×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.91×
Profitability
Earnings per share
-$1.17
Return on assets
-79.47%
Return on equity
-155.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.81×
Quick ratio
9.81×
Cash ratio
1.87×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$69.64M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PMVP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4M
$4.21M
$3.69M
$3.42M
$4.31M
$4.48M
$4.12M
$11.4M
Research and development
$16.06M
$14.68M
$15.33M
$15.83M
$18.21M
$18.4M
$17.44M
$13.77M
Total operating expenses
$20.06M
$18.88M
$19.02M
$19.24M
$22.52M
$22.88M
$21.56M
$25.17M
Operating income
-$20.06M
-$18.88M
-$19.02M
-$19.24M
-$22.52M
-$22.88M
-$21.56M
-$25.17M
Interest expense
$0
$0
$0
$1.23M
$0
$0
$0
$2.29M
Income before taxes
-$34.38M
-$18.08M
-$18.04M
-$18.01M
-$21.07M
-$21.21M
-$19.63M
-$23M
Income taxes
-$7K
$3K
$0
$26K
-$6K
$5K
-$2.2M
$0
Net income
-$34.37M
-$18.09M
-$18.04M
-$18.04M
-$21.06M
-$21.21M
-$17.44M
-$23M
Net income attributable to common shareholders
-$34.37M
-$18.09M
-$18.04M
-$18.04M
-$21.06M
-$21.21M
-$17.44M
-$23M
EBITDA
-$20.04M
-$18.86M
-$18.99M
-$19.21M
-$22.49M
-$22.85M
-$21.53M
-$25.13M
Basic earnings per share
-$0.52
-$0.34
-$0.34
-$0.34
-$0.40
-$0.41
-$0.34
-$0.44
Diluted earnings per share
-$0.52
-$0.34
-$0.34
-$0.34
-$0.40
-$0.41
-$0.34
-$0.44
Recent news
Company coverage with links to the original publishers.
PMV Pharmaceuticals announced that updated Phase 2 results from the PYNNACLE clinical trial of rezatapopt, a p53 reactivator for TP53 Y220C-positive advanced solid tumors, will be presented at the ENA 2026 symposium on November 20, 2026. The presentation will showcase efficacy data across multiple tumor types including ovarian, lung, breast, and endometrial cancers.
PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028.
PMV Pharma announced a public offering of 22.055 million shares of common stock and pre-funded warrants to purchase 19.9 million shares, along with accompanying warrants, expected to raise approximately $50.8 million gross proceeds. The offering is priced at $1.21 per share and is expected to close on or about September 2, 2026.
PMV Pharmaceuticals announced a leadership transition with Laurie Stelzer, a director since 2020, appointed as the new Board Chair, succeeding Rich Heyman effective June 4, 2026. Stelzer brings over 25 years of senior finance and business development experience in biopharmaceuticals. The transition occurs as the company continues enrollment in its PYNNACLE clinical trial for rezatapopt and prepares to submit a New Drug Application for platinum-resistant/refractory ovarian cancer patients in Q1 2027.
PMV Pharmaceuticals reported positive Phase 2 interim data from its PYNNACLE trial evaluating rezatapopt for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutations, achieving a 50% overall response rate among 48 evaluable patients. The company received FDA Orphan Drug Designation and plans to submit a New Drug Application in Q1 2027. However, cash runway extends only to Q2 2027 with $112.9 million in reserves, and the company increased R&D spending while net losses widened to $77.7 million in 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.